Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Endothelin receptor ET-A | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | Endothelin receptor ET-A | 426 aa | 412 aa | 20.1 % |
Echinococcus multilocularis | pyroglutamylated rfamide peptide receptor | Endothelin receptor ET-A | 426 aa | 412 aa | 21.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | sulfite reductase | 0.0222 | 0.2407 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0359 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0359 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0359 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0359 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0181 | 0.0151 | 0.0151 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0359 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0359 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0359 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0318 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0359 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0359 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0318 | 0.7743 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0359 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0359 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0359 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0359 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0359 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0359 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0359 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0178 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0359 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0359 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0359 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0222 | 0.2407 | 0.2407 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0178 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0359 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0359 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0359 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 3000 nM | In vitro ability to antagonise the binding of [125I]-ET-1 to the rat aortic A10 cell membrane endothelin A receptor. | ChEMBL. | 10715156 |
IC50 (binding) | = 3000 nM | In vitro ability to antagonise the binding of [125I]-ET-1 to the rat aortic A10 cell membrane endothelin A receptor. | ChEMBL. | 10715156 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.